• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Patrick P. Gleason Addresses the Impact of Out-of-Pocket Costs on Adherence and Outcomes

Article

Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.

Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.

Related Videos
Refat Rasul Srejon, MPH
Refat Rasul Srejon, MPH
Screenshot of an interview with Nicolas Girard, MD, PhD
Byoung Chul Cho, MD, PhD
Beth Stein, MD, and Ratna Kiran Bhavaraju-Sanka, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.